Prochlorperazine maleate is a drug belonging to the group of phenothiazines, primarily used for treating nausea and vomiting associated with various conditions such as migraine, chemotherapy, surgery etc. The drug helps combat nausea by blocking dopamine receptors in the brain’s vomiting center. With increasing prevalence of nausea and vomiting related illnesses globally, the demand for effective antiemetic drugs like prochlorperazine maleate has surged tremendously.
The global Prochlorperazine Maleate Market is estimated to be valued at US$ 1.46 Bn in 2024 and is expected to exhibit a CAGR of 3.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Growing popularity as an antiemetic drug for chemotherapy-induced nausea and vomiting (CINV) has propelled the demand for prochlorperazine maleate. Prochlorperazine maleate works effectively in combating nausea and vomiting caused by chemotherapy. With rising burden of cancer globally and increasing reliance on chemotherapy as a treatment option, the need for prochlorperazine maleate and other antiemetic drugs have grown substantially. This upsurge in chemotherapy procedures is expected to drive higher demand for prochlorperazine maleate over the forecast period.
Strength: Global Prochlorperazine Maleate Market Size has strong antiemetic properties and is widely used to treat nausea and vomiting. It is available generically which makes it highly affordable.
Weakness: Common side effects include drowsiness, dizziness and restlessness. Long term use can cause neurological side effects and tardive dyskinesia.
Opportunity: Rising incidence of motion sickness, post-operative nausea and vomiting especially in the elderly population presents an opportunity for market growth.
Threats: Increased preference for newer antiemetics with fewer side effects poses a threat. Stiff competition from alternate generics further increases pricing pressures.
The global Prochlorperazine Maleate market is expected to witness steady growth over the forecast period of 2023 to 2030. The global Prochlorperazine Maleate Market is estimated to be valued at US$ 1.46 Bn in 2024 and is expected to exhibit a CAGR of 3.3% over the forecast period 2023 to 2030.
The North America region currently dominates the market owing to high treatment rates for nausea and vomiting. Europe follows next supported by rising geriatric population. Asia Pacific is expected to witness fastest growth led by countries like India and China where growing medical tourism is propelling market expansion.
Key players operating in the Prochlorperazine Maleate market are Polyclean Technologies, Amneal Pharmaceuticals, Mylan, Exelan Pharmaceuticals, Wockhardt and Aurobindo Pharma. Key players are focusing on developing new formulations to improve patient compliance. They are also expanding regional presence through collaborations with local distributors.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it